At a glance
A named research preparation whose component identity needs close attention.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Treat related-compound findings as background unless the study explicitly identifies the same formulation. This distinction is especially important for neurological outcome claims.[3][8][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Neuroxelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 48 mg · 2 source tables
Standard / Gradual Approach (3 mL = 16 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 500 mcg | 3 units (0.03 mL) |
| Weeks 5–8 | 750 mcg | 4.7 units (0.047 mL) |
Frequency: Inject once daily subcutaneously, preferably in the morning. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Alternative Dosing Tiers
| Tier | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Conservative | 250 mcg | 1.6 units (0.016 mL) |
| Typical | 500 mcg | 3.1 units (0.031 mL) |
| Aggressive | 1000 mcg | 6.3 units (0.063 mL) |
Additional schedule context & duration
Concise summary of the once-daily regimen for neuroprotection and cognitive recovery.
- Goal: Support neuroprotection, reduce neuroinflammation, and enhance cognitive recovery following brain injury[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend if desired).
- Dose Range: 250–1000 mcg daily; typical dose is 500 mcg.
- Reconstitution: 3.0 mL per 48 mg vial (16 mg/mL) for practical unit measurements.
- Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated at 2–8 °C; use within 4 weeks of reconstitution.
Suggested daily dosing approach with optional titration.
- Start: 500 mcg daily for Weeks 1–4; assess tolerance.
- Adjust: Increase to 750–1000 mcg daily from Week 5 if well-tolerated and more aggressive support is desired.
- Frequency: Once per day (subcutaneous), preferably morning.
- Cycle Length: 8–12 weeks; re-assess every 8 weeks for extension.
- Timing: Administer at the same time each morning; rotate injection sites.
Preparation
Reconstitution Steps
- Allow lyophilized vial to reach room temperature before opening.
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with concentration (16 mg/mL) and date; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide integrity and potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for months to years[5].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks; avoid freeze–thaw cycles[6].
- Allow vials to reach room temperature before opening to reduce condensation and moisture uptake[5].
- Consider aliquoting into sterile cryovials if not using full volume within 4 weeks.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[10].
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 45° into subcutaneous tissue[10][11].
- Do not aspirate for subcutaneous injections; inject slowly and steadily over ~5 seconds[10].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid tissue irritation[12].
- Use room-temperature solution and allow alcohol to dry before injecting to minimize discomfort.
- Wait 2 seconds after injection before withdrawing the needle; apply gentle pressure with gauze if needed.
Materials & quantity planning
Source materials checklist · 48 mg
Plan based on an 8–12 week daily protocol at the typical 500 mcg dose.
-
Peptide Vials (Neuroxelin, 48 mg each):
- 8 weeks (500 mcg/day): 1 vial (28 mg used; ~58% of vial)
- 12 weeks (500 mcg/day): 1 vial (42 mg used; ~88% of vial)
- 8 weeks (1000 mcg/day): 2 vials (56 mg needed)
-
Insulin Syringes (U-100, 30- or 50-unit recommended):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 1 vial reconstitution: 3 mL → 1 × 10 mL bottle
- 2 vials reconstitution: 6 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 48 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
Drugs (Springer/PubMed) — Efficacy and safety of sovateltide in acute cerebral ischaemic stroke: Phase III clinical trial (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
- 08
- 09
Research publication
PubMed — Phase 1 randomized, double-blind, placebo-controlled study of CN-105 safety and pharmacokinetics (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous injection technique (angle, site, no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Public health resource
CDC — Vaccine administration during vaccination: subcutaneous injection guidance (opens in a new tab)www.cdc.gov
Back to overview ↑ - 12
Research publication
Advances in Therapy (PMC) — Subcutaneous injection of drugs: factors influencing pain sensation at injection site (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.